BAY 1135626
BAY 1135626 is used to synthesize BAY 1129980, and use to anti-tumor research. BAY 1129980 is a Auristatin-based anti-C4.4A (LYPD3) antibody–agent conjugate (ADC), is used to non–small cell lung cancer (NSCLC) research[1].
Product Specifications
CAS Number
1404071-37-9
UNSPSC
12352203
Target
Drug-Linker Conjugates for ADC
Type
ADC Related
Related Pathways
Antibody-drug Conjugate/ADC Related
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/bay-1135626.html
Purity
99.19
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
CO[C@@H]([C@@]1([H])N(CCC1)C(C[C@@H](OC)[C@H]([C@@H](C)CC)N(C)C([C@H](C(C)C)NC([C@H](C(C)C)N(C)CCCC(NNC(CCCCCN2C(C=CC2=O)=O)=O)=O)=O)=O)=O)[C@@H](C)C(N[C@H](C(N)=O)CC3=CNC4=CC=CC=C34)=O
Molecular Formula
C55H86N10O11
Molecular Weight
1063.33
References & Citations
[1]Willuda J, et al. Preclinical Antitumor Efficacy of BAY 1129980-a Novel Auristatin-Based Anti-C4.4A (LYPD3) Antibody-Drug Conjugate for the Treatment of Non-Small Cell Lung Cancer. Mol Cancer Ther. 2017 May. 16 (5) :893-904.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, protect from light)
Scientific Category
ADC Related
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
LY422147 100 µg
Sec8 (EXOC4) (NM_001037126) Human Over-expression Lysate
Sign In for Pricing
View Details 
BNCB1700-500 1x 500 µL
CD44v4 (Marker of Tumor Metastasis) (CD44v4/1700R), Biotin conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC401745-500 1x 500 µL
Epstein-Barr Virus (LMP-1) (CS1-4), CF640R conjugate, 0.1mg/mL
Sign In for Pricing
View Details